Skip to content

Patients › Elbow

鹰嘴滑囊炎

PDF Evidence

Olecranon bursitis — causes, symptoms, and when to seek urgent medical attention for infection.

Updated Jun 2026
一幅手绘插图，描绘了一个无脸的人将弯曲的肘部放在桌子上，肘尖处有一个肿胀的软组织肿块。
鹰嘴滑囊炎：覆盖在肘部骨性突起的充满液体的缓冲垫（滑囊）肿胀，形成此处可见的典型“鹅蛋”样肿块。 Kieran Hirpara 4.0

本页面由机器翻译，尚未经临床医生审核。英文版本为权威版本。

您的感受

您可能会注意到肘尖处有一个肿胀的包块。这种肿胀是由于滑囊内液体积聚所致，滑囊是一个充满液体的小囊，用于缓冲骨骼。该区域按压时可能有压痛感。您可能还会感到疼痛，尤其是当肿胀由感染引起或骨组织失去血液供应时。肿胀与疼痛的组合会使日常生活变得不适。

当肘部肿胀时，简单的动作会变得困难。您可能难以将肘部靠在桌子或书桌上。需要完全弯曲手臂的任务，如伸手到背后扣文胸，可能会引起疼痛。即使是塞衬衫或提起轻物，也可能感觉别扭或不舒服。肿胀会限制您伸直或弯曲手臂的程度。

疼痛往往在使用手臂一段时间后加剧。夜间疼痛也可能加重，使您难以找到舒适的睡眠姿势。侧卧在患侧会对肿胀的滑囊造成直接压迫，这可能非常疼痛。您可能会发现休息手臂有助于减轻不适，但长时间不活动并不总能消除肿胀。如果肿胀持续很长时间，可能表明存在更复杂的问题，需要您的外科医生特别关注。

实际发生了什么

您的肘部有一个充满液体的小囊，称为鹰嘴滑囊。它位于肘骨尖端正上方。可以把它想象成一个微小的水气球，起到缓冲作用。当您弯曲手臂时，它使皮肤能够在骨头上平滑滑动。

当这个囊受到刺激时，会积聚过多的液体。这会导致肘尖肿胀和疼痛。这种情况称为鹰嘴滑囊炎。它可能由突然的撞击引起，例如摔倒时肘部着地。长期倚靠坚硬表面也可能导致此病。有时，感染或其他疾病会诱发此病。

在某些情况下，肿胀不会自行消退。液体可能保持粘稠或转化为瘢痕组织。这称为慢性滑囊炎。您可能会在皮下感觉到一个硬结。这称为鹰嘴索。它可能使肘部感觉僵硬或紧绷。

如果肿胀是由感染引起的，则称为感染性滑囊炎。您的外科医生需要迅速治疗这种情况。未经治疗的感染可能会扩散。在某些情况下，身体会在肘部周围的软组织中形成额外的骨骼。这称为异位骨化。它可能会限制您弯曲手臂的程度。早期切除这些额外的骨骼通常有助于您更快地恢复活动能力。

您的外科医生会检查导致肿胀的原因。大多数病例通过休息、冰敷和加压包扎即可好转。您可能根本不需要手术。如果肿胀反复发作，您的外科医生可能会引流液体。他们还可能使用针头注射药物以缩小滑囊。这称为硬化疗法。

在极少数情况下，需要手术。您的外科医生可能会切除整个滑囊。这称为滑囊切除术。现代技术允许通过小切口进行此手术。恢复通常很快。大多数人在术后不久即可恢复正常活动。然而，约 11.5% 的患者在术后需要再次手术。一些患有瘢痕组织索的患者对结果不太满意。您的外科医生将根据您的具体情况讨论最佳方案。

我们能采取的措施

我们从自我护理和物理治疗开始。您可以休息肘部并冰敷以减轻肿胀。您的物理治疗师将指导您进行轻柔的活动以保持关节灵活。这种方法可避免侵入性操作。最近的文献表明，对于非感染性滑囊炎，非侵入性管理通常是最佳初始步骤。与注射或手术相比，它最大限度地降低了风险。大多数无并发症的感染性滑囊炎仅通过经验性治疗即可消退。在考虑更积极的治疗方案之前，您应给予保守治疗足够的时间以发挥作用。

如果疼痛持续存在，您的外科医生可能会讨论药物治疗。对于细菌感染，抗生素是主要治疗方法。在某些对标准治疗无效的复发性滑囊炎病例中，您的外科医生可能会建议进行滑囊内多西环素硬化治疗。这涉及向滑囊内注射溶液以使其缩小。这是顽固性病例的有效手术替代方案。对于慢性或复发性非感染性滑囊炎，热消融是另一种选择。这使用 50°C 至 52°C 之间的热量来治疗该区域。与开放手术相比，它的并发症更少，且效果相当。虽然较旧的研究支持对非感染性滑囊炎进行注射，但新的证据强调了潜在的不良反应。因此，我们将注射保留在能提供明确益处的特定情况中。

仅在保守治疗失败时才考虑手术。如果您的滑囊炎复发或对药物和休息无改善，则可能需要手术切除。该手术完全移除发炎的滑囊。这是复发性病例的可靠解决方案。手术切除后的结果在功能和外观方面通常都很好。在某些慢性创伤性滑囊炎的选定病例中，滑囊缝合修复是完全移除滑囊的可行替代方案。这种方法结合了功能和美容益处。内镜清创联合加压缝合是另一种微创选择。它允许快速恢复，术后疼痛最小，且复发率低。您的外科医生将根据您的具体状况和病史选择最佳方案。

预期情况

您的预后主要取决于肿胀的原因以及您的管理方式。对于大多数无并发症的感染性滑囊炎，您的外科医生可以仅通过抗生素治疗感染。在这些情况下，不需要手术，只要护理得当，病情通常会好转。如果您的滑囊炎并非由感染引起，最新证据表明，非侵入性治疗通常比注射或手术更安全、更有效，可作为初始治疗手段。

如果您患有复发性滑囊炎且保守治疗无效，您的外科医生可能会讨论介入治疗选项。部分患者会接受滑囊切除术，即切除肿胀的滑囊。约 11.5% 的患者在该手术后需要接受第二次手术。如果您存在称为鹰嘴索（olecranon cords）的特定组织改变，与没有索状改变的患者相比，您对手术切除效果的满意度可能较低。

在某些情况下，肿胀可能会持续存在或复发。如果您的滑囊炎反复复发，这可能提示存在更不寻常的原因，例如特定类型的细菌感染。您的外科医生可能会采集组织样本以排查这些较少见的原因。对于慢性或复发性病例，新技术如水热消融术（使用 50°C 至 52°C 之间的热量）提供了一种并发症少于开放手术的替代方案。另一种选择是内镜下清创术，该方法具有微创性，恢复迅速且复发率低。

虽然较早的研究表明注射和手术是非感染性滑囊炎的标准解决方案，但当前数据突出了这些方法潜在的不良反应。因此，您的外科医生可能会优先采取更简单、非侵入性的步骤。如果确实需要手术，现代方法如内镜下滑囊切除术在研究组中显示无复发或需要再次手术干预的伤口愈合并发症。您的恢复体验会根据所选择的治疗路径而有所不同，但目标始终是以最少侵入性的有效治疗来解决肿胀并恢复舒适。

何时就医

若肘部肿胀经休息后未见改善，请咨询全科医生。若肿胀持续时间较长，即使您身体健康，也应寻求专科医生评估。这可能提示存在不寻常的感染。若出现复发性肿胀，请寻求帮助，因为这可能需要特殊检查。很难判断肿胀是由感染还是其他问题引起的。若皮肤出现类似感染的开放性溃疡，请就医。若肘部突发疼痛或无力，请进行检查。这些症状需要适当评估以确定合适的治疗方案。

Reviewed by AI synthesis (v2) — pending human review · 18 May 2026.

Want the clinical detail? Read the clinician version.

Talk to your treating clinician for advice specific to you.

For an appointment with the CQ Hand + Upper Limb team, ask your GP about a referral or visit www.cqupperlimb.com.

Evidence & references

Overview

  • Non-operative treatment of olecranon fracture in patients aged ≥75 years provided excellent functional results at 6 months, without associated complications [1].
  • Nonsurgical management of olecranon bursitis is significantly more effective and safer than surgical management [2].
  • Nontuberculous mycobacterial olecranon bursitis should be considered in any patient with a swollen bursa and protracted course, regardless of immune status [3].
  • Intrabursal doxycycline sclerotherapy may be an effective alternative to surgical bursectomy for patients with recurrent olecranon bursitis refractory to conservative management [4].
  • Patients who underwent endoscopic olecranon bursectomy experienced no recurrences or wound-healing complications necessitating return to the operating room [5].
  • Empirical management of uncomplicated septic olecranon bursitis was found to be effective with no patients requiring bursectomy, whereas 8 of 11 patients in the traditional aspiration group required bursectomy [6].
  • More recent literature demonstrates adverse effects of intrabursal injections and surgery compared with noninvasive management for initial treatment of nonseptic olecranon bursitis [7].
  • The revision rate after bursectomy for olecranon bursitis was 11.5% [8].
  • Hydrothermal ablation at temperatures between 50C and 52C is a safe treatment option for recurrent or chronic olecranon bursitis with fewer complications than open bursectomy and a comparable efficacy [11].
  • Patients with olecranon cords were less satisfied after surgical excision compared to those without cords [13].
  • Low-profile double-plate osteosynthesis is a safe and effective alternative treatment of olecranon fractures with excellent subjective and objective clinical outcome measures [14].
  • Endoscopic debridement combined with compression suture for the treatment of aseptic olecranon bursitis has several advantages: simple operation, minimal invasiveness, minimal postoperative pain, rapid recovery, a low recurrence rate, and satisfactory overall efficacy [16].

Anatomy & Pathophysiology

  • Posteromedial elbow impingement is a source of disability in overhead throwing athletes [12].
  • Boxers are prone to the development of anterior and posterior elbow impingement lesions involving the coronoid and olecranon process [33].
  • In boxer's elbow, the lead arm is more vulnerable to impingement lesions than the non-lead arm [33].
  • Evaluation and management of elbow injuries in young athletes requires knowledge of immature developing anatomy [25].

Classification

  • Non-operative treatment of olecranon fracture in patients aged ≥75 years provided excellent functional results at 6 months, without associated complications [1].
  • Nonsurgical management of olecranon bursitis is significantly more effective and safer than surgical management [2].
  • Nontuberculous mycobacterial olecranon bursitis should be considered in any patient with a swollen bursa and protracted course, regardless of immune status [3].
  • Intrabursal doxycycline sclerotherapy may be an effective alternative to surgical bursectomy for patients with recurrent olecranon bursitis refractory to conservative management [4].
  • Patients who underwent endoscopic olecranon bursectomy for recalcitrant olecranon bursitis experienced no recurrences or wound-healing complications necessitating return to the operating room [5].
  • Empirical management of uncomplicated septic olecranon bursitis was found to be effective with no patients requiring bursectomy, whereas 8 of 11 patients in the traditional aspiration group required bursectomy [6].
  • More recent literature demonstrates adverse effects of intrabursal injections and surgery compared with noninvasive management for initial treatment of nonseptic olecranon bursitis [7].
  • The revision rate after bursectomy for olecranon bursitis was 11.5% [8].
  • Excision has been curative for all lesions of the olecranon bursa, whereas multiple medications have been tried for cutaneous and systemic infections without clear-cut success [9].
  • Distinguishing between septic and aseptic olecranon bursitis can be difficult because the physical and laboratory data overlap [10].
  • Posteromedial elbow impingement is a source of disability in the overhead throwing athlete [12].
  • The first treatment line for olecranon bursitis is conservative, including ice, rest, anti-inflammatory and analgesic drugs and, occasionally, bursal fluid aspiration [15].
  • Pyoderma gangrenosum must be considered in the differential diagnosis whenever a patient presents with ulcerative cutaneous lesions that resemble an infectious process such as olecranon bursitis [17].
  • The available evidence did not support the central European concept of immediate bursectomy in cases of septic bursitis [22].

Clinical Presentation

  • Non-operative treatment of olecranon fracture in patients aged ≥75 years provided excellent functional results at 6 months, without associated complications [1].
  • Nonsurgical management of olecranon bursitis is significantly more effective and safer than surgical management [2].
  • Nontuberculous mycobacterial olecranon bursitis should be considered in any patient with a swollen bursa and protracted course, regardless of immune status [3].
  • Empirical management of uncomplicated septic olecranon bursitis was found to be effective with no patients requiring bursectomy, whereas 8 of 11 patients in the traditional aspiration group required bursectomy [6].
  • Older studies showed resolution with injections and surgery, but more recent literature demonstrates adverse effects of intrabursal injections and surgery compared with noninvasive management for initial treatment of nonseptic olecranon bursitis [7].
  • The revision rate after bursectomy for olecranon bursitis was 11.5% [8].
  • Excision has been curative for all lesions of the olecranon bursa, whereas multiple medications have been tried for cutaneous and systemic infections without clear-cut success [9].
  • Distinguishing between septic and aseptic olecranon bursitis can be difficult because the physical and laboratory data overlap [10].
  • The first treatment line for olecranon bursitis is conservative, including ice, rest, anti-inflammatory and analgesic drugs and, occasionally, bursal fluid aspiration [15].
  • PG must be considered in the differential diagnosis whenever a patient presents with ulcerative cutaneous lesions that resemble an infectious process such as olecranon bursitis [17].
  • Diagnosis and proper management of the infected bursa and dermatitis have prevented recurrence [31].
  • In the rheumatoid patient, septic arthritis of the elbow joint can mimic septic olecranon bursitis, and the fact that the elbow joint may also be involved should be suspected in the rheumatoid patient who has what appears to be a septic olecranon bursitis [34].

Investigations

  • Distinguishing between septic and aseptic olecranon bursitis can be difficult because physical and laboratory data overlap [10].
  • Nontuberculous mycobacterial olecranon bursitis should be considered in any patient with a swollen bursa and protracted course, regardless of immune status [3].
  • Pyoderma gangrenosum must be considered in the differential diagnosis whenever a patient presents with ulcerative cutaneous lesions that resemble an infectious process such as olecranon bursitis [17].
  • Early use of MRI and cautious interpretation of posterior elbow palpation signs are crucial parts of the diagnosis of osteochondral injury of the elbow trochlea [21].

Treatment

Non-Operative Management

  • Nonsurgical management of olecranon bursitis is significantly more effective and safer than surgical management [2].
  • Noninvasive management is preferred for the initial treatment of nonseptic olecranon bursitis due to adverse effects associated with intrabursal injections and surgery [7].
  • The first treatment line for olecranon bursitis is conservative, including ice, rest, anti-inflammatory and analgesic drugs, and occasionally bursal fluid aspiration [15].
  • Empirical management of uncomplicated septic olecranon bursitis without aspiration was effective, with no patients requiring bursectomy [6].
  • In a comparison of empirical management versus traditional aspiration for uncomplicated septic olecranon bursitis, 8 of 11 patients in the traditional aspiration group required bursectomy [6].

Surgical and Interventional Management

  • Intrabursal doxycycline sclerotherapy may be an effective alternative to surgical bursectomy for patients with recurrent olecranon bursitis refractory to conservative management [4].
  • Hydrothermal ablation at temperatures between 50°C and 52°C is a safe treatment option for recurrent or chronic olecranon bursitis, offering fewer complications than open bursectomy and comparable efficacy [11].
  • Endoscopic debridement combined with compression suture for recalcitrant aseptic olecranon bursitis offers minimal invasiveness, minimal postoperative pain, rapid recovery, a low recurrence rate, and satisfactory overall efficacy [16].
  • Patients undergoing endoscopic olecranon bursectomy for recalcitrant olecranon bursitis experienced no recurrences or wound-healing complications necessitating return to the operating room [5].
  • The revision rate after bursectomy for olecranon bursitis is 11.5% [8].
  • Excision has been curative for lesions of the olecranon bursa, whereas multiple medications have been tried for cutaneous and systemic infections without clear-cut success [9].

Diagnostic Considerations Relevant to Treatment

  • Distinguishing between septic and aseptic olecranon bursitis can be difficult because physical and laboratory data overlap [10].
  • Nontuberculous mycobacterial olecranon bursitis should be considered in any patient with a swollen bursa and protracted course, regardless of immune status [3].

Complications

  • Non-operative treatment of olecranon fracture in patients aged ≥75 years provided excellent functional results at 6 months without associated complications [1].
  • Nonsurgical management of olecranon bursitis is significantly more effective and safer than surgical management [2].
  • Intrabursal injections and surgery have adverse effects compared with noninvasive management for initial treatment of nonseptic olecranon bursitis [7].
  • The revision rate after bursectomy for olecranon bursitis was 11.5% [8].
  • Patients with olecranon cords were less satisfied after surgical excision compared to those without cords [13].
  • Plating of the olecranon leads to predictable union, though the most common complication was lack of full extension in 39% of patients [19].

Recovery

Non-Operative Management

  • Non-surgical management of olecranon bursitis is significantly more effective and safer than surgical management [2].
  • More recent literature demonstrates adverse effects of intrabursal injections and surgery compared with noninvasive management for initial treatment of nonseptic olecranon bursitis [7].
  • Empirical management of uncomplicated septic olecranon bursitis without aspiration was found to be effective, with no patients requiring bursectomy [6].
  • In a comparison group, 8 of 11 patients in the traditional aspiration group required bursectomy for uncomplicated septic olecranon bursitis [6].
  • The available evidence did not support the central European concept of immediate bursectomy in cases of septic bursitis [22].

Interventional and Operative Management

  • Intrabursal doxycycline sclerotherapy may be an effective alternative to surgical bursectomy for patients with recurrent olecranon bursitis refractory to conservative management [4].
  • Hydrothermal ablation at temperatures between 50C and 52C is a safe treatment option for recurrent or chronic olecranon bursitis with fewer complications than open bursectomy and comparable efficacy [11].
  • Patients who underwent endoscopic olecranon bursectomy for recalcitrant olecranon bursitis experienced no recurrences or wound-healing complications necessitating return to the operating room [5].
  • The revision rate after bursectomy for olecranon bursitis was 11.5% [8].
  • Patients with olecranon cords were less satisfied after surgical excision compared to those without cords [13].
  • Excision has been curative for all lesions of the olecranon bursa in cases of protothecal olecranon bursitis [9].

Specific Etiologies and Considerations

  • Nontuberculous mycobacterial olecranon bursitis should be considered in any patient with a swollen bursa and protracted course, regardless of immune status [3].

Key Evidence

  • [L4] Non-operative treatment of olecranon fracture in patients aged ≥75 years provided excellent functional results at 6 months, without associated complications. [1] (10.1016/j.otsr.2017.10.015)
  • [L4] Based primarily on level IV evidence, nonsurgical management of olecranon bursitis is significantly more effective and safer than surgical management. [2] (10.1007/s00402-014-2088-3)
  • [L4] Nontuberculous mycobacterial olecranon bursitis should be considered in any patient with a swollen bursa and protracted course, regardless of immune status. [3] (10.1016/j.jse.2008.07.009)
  • [L4] This may be an effective alternative to surgical bursectomy for patients with recurrent olecranon bursitis refractory to conservative management. [4] (10.1016/j.jhsg.2024.03.006)
  • [L4] In this population, patients who underwent endoscopic olecranon bursectomy experienced no recurrences or wound-healing complications necessitating return to the operating room. [5] (10.1016/j.asmr.2023.100832)
  • [L4] Empirical management of uncomplicated septic olecranon bursitis was found to be effective with no patients requiring bursectomy, whereas 8 of 11 patients in the traditional aspiration group required bursectomy. [6] (10.1016/j.jhsa.2019.06.012)
  • [L5] Older studies showed resolution with injections and surgery, but more recent literature demonstrates adverse effects of intrabursal injections and surgery compared with noninvasive management for initial treatment of nonseptic olecranon bursitis. [7] (10.1016/j.jhsa.2021.02.006)
  • [L3] The revision rate after bursectomy for olecranon bursitis was 11.5%. [8] (10.1016/j.jse.2020.09.033)
  • [Case_report] Excision has been curative for all lesions of the olecranon bursa, whereas multiple medications have been tried for cutaneous and systemic infections without clear-cut success. [9] (10.2106/00004623-198062050-00024)
  • [L5] Distinguishing between septic and aseptic olecranon bursitis can be difficult because the physical and laboratory data overlap. [10] (10.1016/j.jse.2015.08.032)
  • [L4] Hydrothermal ablation at temperatures between 50C and 52C is a safe treatment option for recurrent or chronic olecranon bursitis with fewer complications than open bursectomy and a comparable efficacy. [11] (10.1016/j.jse.2024.03.021)
  • [L4] Posteromedial elbow impingement is a source of disability in the overhead throwing athlete. [12] (10.1016/j.arthro.2011.06.012)
  • [L4] Patients with olecranon cords were less satisfied after surgical excision compared to those without cords. [13] (10.1016/j.jse.2015.04.016)
  • [L3] Low-profile double-plate osteosynthesis is a safe and effective alternative treatment of olecranon fractures with excellent subjective and objective clinical outcome measures. [14] (10.1016/j.otsr.2019.08.019)
  • [L4] The first treatment line for olecranon bursitis is conservative, including ice, rest, anti-inflammatory and analgesic drugs and, occasionally, bursal fluid aspiration. [15] (10.1016/j.surge.2012.02.002)
  • [L4] Endoscopic debridement combined with compression suture for the treatment of aseptic olecranon bursitis has several advantages: simple operation, minimal invasiveness, minimal postoperative pain, rapid recovery, a low recurrence rate, and satisfactory overall efficacy. [16] (10.1186/s13018-024-05090-3)
  • [Case_report] PG must be considered in the differential diagnosis whenever a patient presents with ulcerative cutaneous lesions that resemble an infectious process such as olecranon bursitis. [17] (10.1016/j.jse.2014.06.032)
  • [L3] Plating of the olecranon leads to predictable union, though the most common complication was lack of full extension in 39% of patients. [19] (10.1016/j.injury.2016.04.015)
  • [Case_report] It also emphasizes the early use of MRI and the cautious interpretation of posterior elbow palpation signs as a crucial part of the diagnosis of this lesion. [21] (10.1016/j.jse.2010.09.015)
  • [L1] The available evidence did not support the central European concept of immediate bursectomy in cases of septic bursitis. [22] (10.1007/s00402-013-1882-7)
  • [L5] Evaluation and management of elbow injuries in young athletes requires knowledge of the immature developing anatomy, injury pathophysiology, and established treatment algorithms for each diagnosis. [25] (10.1016/j.csm.2010.06.010)
  • [L4] Diagnosis and proper management of the infected bursa and dermatitis have prevented recurrence. [31] (10.1016/j.jse.2011.10.013)
  • [L4] Boxers are prone to development of anterior and posterior elbow impingement lesions, with the lead arm being more vulnerable. [33] (10.1016/j.jse.2016.09.035)
  • [L4] In the rheumatoid patient, septic arthritis of the elbow joint can mimic septic olecranon bursitis, and the fact that the elbow joint may also be involved should be suspected in the rheumatoid patient who has what appears to be a septic olecranon bursitis. [34] (10.2106/00004623-198062060-00022)

References

[1] Results of non-operative treatment of olecranon fracture in over 75-year-olds. Orthopaedics & Traumatology: Surgery & Research. 2018. DOI: 10.1016/j.otsr.2017.10.015 [2] Treatment of olecranon bursitis: a systematic review. Archives of Orthopaedic and Trauma Surgery. 2014. DOI: 10.1007/s00402-014-2088-3 [3] Nontuberculous mycobacterial olecranon bursitis: Case reports and literature review. Journal of Shoulder and Elbow Surgery. 2009. DOI: 10.1016/j.jse.2008.07.009 [4] Intrabursal Doxycycline Sclerotherapy for Recurrent Olecranon Bursitis of the Elbow: A Case Control Study. Journal of Hand Surgery Global Online. 2024. DOI: 10.1016/j.jhsg.2024.03.006 [5] No Wound Healing Complications or Recurrences Were Seen and a High Level of Satisfaction Was Reported in Patients Who Underwent Endoscopic Olecranon Bursectomy for Recalcitrant Olecranon Bursitis. Arthroscopy, Sports Medicine, and Rehabilitation. 2024. DOI: 10.1016/j.asmr.2023.100832 [6] Empirical Treatment of Uncomplicated Septic Olecranon Bursitis Without Aspiration. The Journal of Hand Surgery. 2020. DOI: 10.1016/j.jhsa.2019.06.012 [7] Clinical Management of Olecranon Bursitis: A Review. The Journal of Hand Surgery. 2021. DOI: 10.1016/j.jhsa.2021.02.006 [8] Factors associated with revision surgery for olecranon bursitis after bursectomy. Journal of Shoulder and Elbow Surgery. 2021. DOI: 10.1016/j.jse.2020.09.033 [9] Protothecal olecranon bursitis. A case report and review of the literature.. The Journal of Bone & Joint Surgery. 1980. DOI: 10.2106/00004623-198062050-00024 [10] Olecranon bursitis. Journal of Shoulder and Elbow Surgery. 2016. DOI: 10.1016/j.jse.2015.08.032 [11] Hydrothermal ablation in recurrent or chronic olecranon bursitis: a prospective study. Journal of Shoulder and Elbow Surgery. 2024. DOI: 10.1016/j.jse.2024.03.021 [12] Posteromedial Elbow Impingement: Magnetic Resonance Imaging Findings in Overhead Throwing Athletes and Results of Arthroscopic Treatment. Arthroscopy. 2011. DOI: 10.1016/j.arthro.2011.06.012 [13] The existence of cords in olecranon bursae. Journal of Shoulder and Elbow Surgery. 2015. DOI: 10.1016/j.jse.2015.04.016 [14] Clinical evaluation of double-plate osteosynthesis for olecranon fractures: A retrospective case-control study. Orthopaedics & Traumatology: Surgery & Research. 2019. DOI: 10.1016/j.otsr.2019.08.019 [15] Diagnosis and management of olecranon bursitis. The Surgeon. 2012. DOI: 10.1016/j.surge.2012.02.002 [16] Clinical efficacy of endoscopic debridement combined with compression suture in the treatment of recalcitrant aseptic olecranon bursitis. Journal of Orthopaedic Surgery and Research. 2024. DOI: 10.1186/s13018-024-05090-3 [17] Case report: misdiagnosed olecranon bursitis: pyoderma gangrenosum. Journal of Shoulder and Elbow Surgery. 2014. DOI: 10.1016/j.jse.2014.06.032 [19] Outcomes after plating of olecranon fractures: A multicenter evaluation. Injury. 2016. DOI: 10.1016/j.injury.2016.04.015 [21] Arthroscopic debridement for osteochondral injury of the elbow trochlea: a case report with a long-term follow-up. Journal of Shoulder and Elbow Surgery. 2011. DOI: 10.1016/j.jse.2010.09.015 [22] Prepatellar and olecranon bursitis: literature review and development of a treatment algorithm. Archives of Orthopaedic and Trauma Surgery. 2013. DOI: 10.1007/s00402-013-1882-7 [25] Pediatric Sports Elbow Injuries. Clinics in Sports Medicine. 2010. DOI: 10.1016/j.csm.2010.06.010 [31] Septic olecranon bursitis, contact dermatitis, and pneumonitis in a gas turbine engine mechanic. Journal of Shoulder and Elbow Surgery. 2012. DOI: 10.1016/j.jse.2011.10.013 [33] Boxer's elbow: internal impingement of the coronoid and olecranon process. A report of seven cases. Journal of Shoulder and Elbow Surgery. 2017. DOI: 10.1016/j.jse.2016.09.035 [34] Septic arthritis presenting as olecranon bursitis in patients with rheumatoid arthritis. A report of three cases.. The Journal of Bone & Joint Surgery. 1980. DOI: 10.2106/00004623-198062060-00022

Creative Commons BY-NC 4.0

CC Creative Commons licence
BY Attribution — you must credit the source
NC NonCommercial — not for commercial use

Attribution-NonCommercial 4.0 International

Creative Commons Corporation ("Creative Commons") is not a law firm and does not provide legal services or legal advice. Distribution of Creative Commons public licenses does not create a lawyer-client or other relationship. Creative Commons makes its licenses and related information available on an "as-is" basis. Creative Commons gives no warranties regarding its licenses, any material licensed under their terms and conditions, or any related information. Creative Commons disclaims all liability for damages resulting from their use to the fullest extent possible.

Using Creative Commons Public Licenses

Creative Commons public licenses provide a standard set of terms and conditions that creators and other rights holders may use to share original works of authorship and other material subject to copyright and certain other rights specified in the public license below. The following considerations are for informational purposes only, are not exhaustive, and do not form part of our licenses.

Considerations for licensors: Our public licenses are intended for use by those authorized to give the public permission to use material in ways otherwise restricted by copyright and certain other rights. Our licenses are irrevocable. Licensors should read and understand the terms and conditions of the license they choose before applying it. Licensors should also secure all rights necessary before applying our licenses so that the public can reuse the material as expected. Licensors should clearly mark any material not subject to the license. This includes other CC- licensed material, or material used under an exception or limitation to copyright. More considerations for licensors: wiki.creativecommons.org/Considerations_for_licensors

Considerations for the public: By using one of our public licenses, a licensor grants the public permission to use the licensed material under specified terms and conditions. If the licensor's permission is not necessary for any reason--for example, because of any applicable exception or limitation to copyright--then that use is not regulated by the license. Our licenses grant only permissions under copyright and certain other rights that a licensor has authority to grant. Use of the licensed material may still be restricted for other reasons, including because others have copyright or other rights in the material. A licensor may make special requests, such as asking that all changes be marked or described. Although not required by our licenses, you are encouraged to respect those requests where reasonable. More considerations for the public: wiki.creativecommons.org/Considerations_for_licensees

Creative Commons Attribution-NonCommercial 4.0 International Public License

By exercising the Licensed Rights (defined below), You accept and agree to be bound by the terms and conditions of this Creative Commons Attribution-NonCommercial 4.0 International Public License ("Public License"). To the extent this Public License may be interpreted as a contract, You are granted the Licensed Rights in consideration of Your acceptance of these terms and conditions, and the Licensor grants You such rights in consideration of benefits the Licensor receives from making the Licensed Material available under these terms and conditions.

Section 1 -- Definitions.

a. Adapted Material means material subject to Copyright and Similar Rights that is derived from or based upon the Licensed Material and in which the Licensed Material is translated, altered, arranged, transformed, or otherwise modified in a manner requiring permission under the Copyright and Similar Rights held by the Licensor. For purposes of this Public License, where the Licensed Material is a musical work, performance, or sound recording, Adapted Material is always produced where the Licensed Material is synched in timed relation with a moving image.

b. Adapter's License means the license You apply to Your Copyright and Similar Rights in Your contributions to Adapted Material in accordance with the terms and conditions of this Public License.

c. Copyright and Similar Rights means copyright and/or similar rights closely related to copyright including, without limitation, performance, broadcast, sound recording, and Sui Generis Database Rights, without regard to how the rights are labeled or categorized. For purposes of this Public License, the rights specified in Section 2(b)(1)-(2) are not Copyright and Similar Rights.

d. Effective Technological Measures means those measures that, in the absence of proper authority, may not be circumvented under laws fulfilling obligations under Article 11 of the WIPO Copyright Treaty adopted on December 20, 1996, and/or similar international agreements.

e. Exceptions and Limitations means fair use, fair dealing, and/or any other exception or limitation to Copyright and Similar Rights that applies to Your use of the Licensed Material.

f. Licensed Material means the artistic or literary work, database, or other material to which the Licensor applied this Public License.

g. Licensed Rights means the rights granted to You subject to the terms and conditions of this Public License, which are limited to all Copyright and Similar Rights that apply to Your use of the Licensed Material and that the Licensor has authority to license.

h. Licensor means the individual(s) or entity(ies) granting rights under this Public License.

i. NonCommercial means not primarily intended for or directed towards commercial advantage or monetary compensation. For purposes of this Public License, the exchange of the Licensed Material for other material subject to Copyright and Similar Rights by digital file-sharing or similar means is NonCommercial provided there is no payment of monetary compensation in connection with the exchange.

j. Share means to provide material to the public by any means or process that requires permission under the Licensed Rights, such as reproduction, public display, public performance, distribution, dissemination, communication, or importation, and to make material available to the public including in ways that members of the public may access the material from a place and at a time individually chosen by them.

k. Sui Generis Database Rights means rights other than copyright resulting from Directive 96/9/EC of the European Parliament and of the Council of 11 March 1996 on the legal protection of databases, as amended and/or succeeded, as well as other essentially equivalent rights anywhere in the world.

l. You means the individual or entity exercising the Licensed Rights under this Public License. Your has a corresponding meaning.

Section 2 -- Scope.

a. License grant.

1. Subject to the terms and conditions of this Public License, the Licensor hereby grants You a worldwide, royalty-free, non-sublicensable, non-exclusive, irrevocable license to exercise the Licensed Rights in the Licensed Material to:

a. reproduce and Share the Licensed Material, in whole or in part, for NonCommercial purposes only; and

b. produce, reproduce, and Share Adapted Material for NonCommercial purposes only.

2. Exceptions and Limitations. For the avoidance of doubt, where Exceptions and Limitations apply to Your use, this Public License does not apply, and You do not need to comply with its terms and conditions.

3. Term. The term of this Public License is specified in Section 6(a).

4. Media and formats; technical modifications allowed. The Licensor authorizes You to exercise the Licensed Rights in all media and formats whether now known or hereafter created, and to make technical modifications necessary to do so. The Licensor waives and/or agrees not to assert any right or authority to forbid You from making technical modifications necessary to exercise the Licensed Rights, including technical modifications necessary to circumvent Effective Technological Measures. For purposes of this Public License, simply making modifications authorized by this Section 2(a) (4) never produces Adapted Material.

5. Downstream recipients.

a. Offer from the Licensor -- Licensed Material. Every recipient of the Licensed Material automatically receives an offer from the Licensor to exercise the Licensed Rights under the terms and conditions of this Public License.

b. No downstream restrictions. You may not offer or impose any additional or different terms or conditions on, or apply any Effective Technological Measures to, the Licensed Material if doing so restricts exercise of the Licensed Rights by any recipient of the Licensed Material.

6. No endorsement. Nothing in this Public License constitutes or may be construed as permission to assert or imply that You are, or that Your use of the Licensed Material is, connected with, or sponsored, endorsed, or granted official status by, the Licensor or others designated to receive attribution as provided in Section 3(a)(1)(A)(i).

b. Other rights.

1. Moral rights, such as the right of integrity, are not licensed under this Public License, nor are publicity, privacy, and/or other similar personality rights; however, to the extent possible, the Licensor waives and/or agrees not to assert any such rights held by the Licensor to the limited extent necessary to allow You to exercise the Licensed Rights, but not otherwise.

2. Patent and trademark rights are not licensed under this Public License.

3. To the extent possible, the Licensor waives any right to collect royalties from You for the exercise of the Licensed Rights, whether directly or through a collecting society under any voluntary or waivable statutory or compulsory licensing scheme. In all other cases the Licensor expressly reserves any right to collect such royalties, including when the Licensed Material is used other than for NonCommercial purposes.

Section 3 -- License Conditions.

Your exercise of the Licensed Rights is expressly made subject to the following conditions.

a. Attribution.

1. If You Share the Licensed Material (including in modified form), You must:

a. retain the following if it is supplied by the Licensor with the Licensed Material:

i. identification of the creator(s) of the Licensed Material and any others designated to receive attribution, in any reasonable manner requested by the Licensor (including by pseudonym if designated);

ii. a copyright notice;

iii. a notice that refers to this Public License;

iv. a notice that refers to the disclaimer of warranties;

v. a URI or hyperlink to the Licensed Material to the extent reasonably practicable;

b. indicate if You modified the Licensed Material and retain an indication of any previous modifications; and

c. indicate the Licensed Material is licensed under this Public License, and include the text of, or the URI or hyperlink to, this Public License.

2. You may satisfy the conditions in Section 3(a)(1) in any reasonable manner based on the medium, means, and context in which You Share the Licensed Material. For example, it may be reasonable to satisfy the conditions by providing a URI or hyperlink to a resource that includes the required information.

3. If requested by the Licensor, You must remove any of the information required by Section 3(a)(1)(A) to the extent reasonably practicable.

4. If You Share Adapted Material You produce, the Adapter's License You apply must not prevent recipients of the Adapted Material from complying with this Public License.

Section 4 -- Sui Generis Database Rights.

Where the Licensed Rights include Sui Generis Database Rights that apply to Your use of the Licensed Material:

a. for the avoidance of doubt, Section 2(a)(1) grants You the right to extract, reuse, reproduce, and Share all or a substantial portion of the contents of the database for NonCommercial purposes only;

b. if You include all or a substantial portion of the database contents in a database in which You have Sui Generis Database Rights, then the database in which You have Sui Generis Database Rights (but not its individual contents) is Adapted Material; and

c. You must comply with the conditions in Section 3(a) if You Share all or a substantial portion of the contents of the database.

For the avoidance of doubt, this Section 4 supplements and does not replace Your obligations under this Public License where the Licensed Rights include other Copyright and Similar Rights.

Section 5 -- Disclaimer of Warranties and Limitation of Liability.

a. UNLESS OTHERWISE SEPARATELY UNDERTAKEN BY THE LICENSOR, TO THE EXTENT POSSIBLE, THE LICENSOR OFFERS THE LICENSED MATERIAL AS-IS AND AS-AVAILABLE, AND MAKES NO REPRESENTATIONS OR WARRANTIES OF ANY KIND CONCERNING THE LICENSED MATERIAL, WHETHER EXPRESS, IMPLIED, STATUTORY, OR OTHER. THIS INCLUDES, WITHOUT LIMITATION, WARRANTIES OF TITLE, MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, NON-INFRINGEMENT, ABSENCE OF LATENT OR OTHER DEFECTS, ACCURACY, OR THE PRESENCE OR ABSENCE OF ERRORS, WHETHER OR NOT KNOWN OR DISCOVERABLE. WHERE DISCLAIMERS OF WARRANTIES ARE NOT ALLOWED IN FULL OR IN PART, THIS DISCLAIMER MAY NOT APPLY TO YOU.

b. TO THE EXTENT POSSIBLE, IN NO EVENT WILL THE LICENSOR BE LIABLE TO YOU ON ANY LEGAL THEORY (INCLUDING, WITHOUT LIMITATION, NEGLIGENCE) OR OTHERWISE FOR ANY DIRECT, SPECIAL, INDIRECT, INCIDENTAL, CONSEQUENTIAL, PUNITIVE, EXEMPLARY, OR OTHER LOSSES, COSTS, EXPENSES, OR DAMAGES ARISING OUT OF THIS PUBLIC LICENSE OR USE OF THE LICENSED MATERIAL, EVEN IF THE LICENSOR HAS BEEN ADVISED OF THE POSSIBILITY OF SUCH LOSSES, COSTS, EXPENSES, OR DAMAGES. WHERE A LIMITATION OF LIABILITY IS NOT ALLOWED IN FULL OR IN PART, THIS LIMITATION MAY NOT APPLY TO YOU.

c. The disclaimer of warranties and limitation of liability provided above shall be interpreted in a manner that, to the extent possible, most closely approximates an absolute disclaimer and waiver of all liability.

Section 6 -- Term and Termination.

a. This Public License applies for the term of the Copyright and Similar Rights licensed here. However, if You fail to comply with this Public License, then Your rights under this Public License terminate automatically.

b. Where Your right to use the Licensed Material has terminated under Section 6(a), it reinstates:

1. automatically as of the date the violation is cured, provided it is cured within 30 days of Your discovery of the violation; or

2. upon express reinstatement by the Licensor.

For the avoidance of doubt, this Section 6(b) does not affect any right the Licensor may have to seek remedies for Your violations of this Public License.

c. For the avoidance of doubt, the Licensor may also offer the Licensed Material under separate terms or conditions or stop distributing the Licensed Material at any time; however, doing so will not terminate this Public License.

d. Sections 1, 5, 6, 7, and 8 survive termination of this Public License.

Section 7 -- Other Terms and Conditions.

a. The Licensor shall not be bound by any additional or different terms or conditions communicated by You unless expressly agreed.

b. Any arrangements, understandings, or agreements regarding the Licensed Material not stated herein are separate from and independent of the terms and conditions of this Public License.

Section 8 -- Interpretation.

a. For the avoidance of doubt, this Public License does not, and shall not be interpreted to, reduce, limit, restrict, or impose conditions on any use of the Licensed Material that could lawfully be made without permission under this Public License.

b. To the extent possible, if any provision of this Public License is deemed unenforceable, it shall be automatically reformed to the minimum extent necessary to make it enforceable. If the provision cannot be reformed, it shall be severed from this Public License without affecting the enforceability of the remaining terms and conditions.

c. No term or condition of this Public License will be waived and no failure to comply consented to unless expressly agreed to by the Licensor.

d. Nothing in this Public License constitutes or may be interpreted as a limitation upon, or waiver of, any privileges and immunities that apply to the Licensor or You, including from the legal processes of any jurisdiction or authority.

Creative Commons is not a party to its public licenses. Notwithstanding, Creative Commons may elect to apply one of its public licenses to material it publishes and in those instances will be considered the “Licensor.” The text of the Creative Commons public licenses is dedicated to the public domain under the CC0 Public Domain Dedication. Except for the limited purpose of indicating that material is shared under a Creative Commons public license or as otherwise permitted by the Creative Commons policies published at creativecommons.org/policies, Creative Commons does not authorize the use of the trademark "Creative Commons" or any other trademark or logo of Creative Commons without its prior written consent including, without limitation, in connection with any unauthorized modifications to any of its public licenses or any other arrangements, understandings, or agreements concerning use of licensed material. For the avoidance of doubt, this paragraph does not form part of the public licenses.

Creative Commons may be contacted at creativecommons.org.